[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 3 sources · 25 days · First seen · Last updated

Tirzepatide clinical research and studies

Overview

Clinical research regarding the drug tirzepatide has progressed from large-scale data analysis to specific real-world population studies.

A study published in ‘The BMJ’ involving over 52,000 patients indicated that tirzepatide provides cardiovascular benefits for type 2 diabetes patients, showing a 32% relative risk reduction in major cardiovascular events compared to sitagliptin. The research also noted a significant reduction in infection-related hospitalizations and mortality.

Building on such clinical findings, the REAL-TIRZEPY study has commenced in Paraguay. This prospective research aims to evaluate the efficacy, safety, and tolerability of tirzepatide under real-world conditions. The study involves 160 participants across two cohorts—individuals with obesity and those with type 2 diabetes—to measure changes in body weight and HbA1c levels.

Entities

Laboratorio de Productos Eticos C. E. I. S. A. · Mounjaro · Hospital de Clínicas · Ana de Hollanda · Paraguay

Timeline

  1. 7 days ago

    [HEALTH] 3 sources
    Paraguay launches REAL-TIRZEPY study on diabetes and obesity

    The REAL-TIRZEPY study in Paraguay is recruiting participants to evaluate the efficacy and safety of tirzepatide for treating obesity and type 2 diabetes under real-world conditions.

  2. about 1 month ago

    [HEALTH] 2 sources
    Tirzepatide reduces cardiovascular risks in diabetes patients

    A study involving over 52,000 patients shows Tirzepatide reduces cardiovascular event risks by 32% and significantly lowers infection-related hospitalizations in type 2 diabetes patients.

Sources

diarioparaguayo.com · revistaplus.com.py · ultimahora.com.py